Cargando…

753. Impact of COVID-19 on Healthcare Facility-Onset Clostridiodes difficile Infection

BACKGROUND: It is estimated that the majority of hospitalized COVID-19 patients around the world received antibiotics despite the fact that bacterial co-infections are rare. This can lead to increased antimicrobial resistance and Clostridioides difficile infections (CDI). Gastrointestinal symptoms o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suleyman, Geehan, Khansa, Rafa, Mayur, Ramesh, Brar, Indira, Kenney, Rachel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644264/ http://dx.doi.org/10.1093/ofid/ofab466.950

Ejemplares similares

670. Clinical Characteristics and Outcomes in Patients with Healthcare Facility-Onset Clostridiodes difficile Infections
por: Joshi, Seema, et al.
Publicado: (2023)

770. Impact of COVID-19 Pandemic on Central Line-associated Bloodstream Infections in Metropolitan Detroit
por: Suleyman, Geehan, et al.
Publicado: (2021)

779. COVID-19 Pandemic and Catheter-associated Urinary Tract Infection Trends
por: Suleyman, Geehan, et al.
Publicado: (2021)

522. Impact of a Multicomponent Intervention Bundle on Healthcare Facility-Onset Clostridium difficile Rates
por: Keegan, Ann, et al.
Publicado: (2018)

779. Clostridiodes difficile: Is it time for surveillance! Cost-benefit analysis
por: Yassin, Mohamed, et al.
Publicado: (2020)

2393. Dimensions of Cumulative Antibiotic Exposure and Risk of Hospital Onset Clostridiodes Difficile
por: Song, Jiyoun, et al.
Publicado: (2019)

749. A Nurse-Driven Protocol for Early Detection of Clostridiodes difficile Infections
por: Beckman, Shannon, et al.
Publicado: (2021)

747. Association of Clostridiodes difficile Infection Incidence With Renewed Vigor in Infection Prevention Practices With the Onset of the COVID-19 Pandemic
por: Khan, Ahmed A, et al.
Publicado: (2021)

972. Asymptomatic Carriage of Clostridiodes difficile and Risk of Subsequent Infection
por: Espiritu, Katrina, et al.
Publicado: (2018)

706. Effect of the Covid-19 Pandemic on Rates of Recurrent Clostridiodes difficile Infection in the Veterans Affairs System
por: Drekonja, Dimitri M, et al.
Publicado: (2021)

798. Metronidazole Exposure Prior to Clostridiodes difficile Infection (CDI) is a Risk Factor for Severe C. difficile Disease in Cancer Patients
por: Francisco, Denise Marie A, et al.
Publicado: (2020)

569. Characterization of COVID-19 Vaccine Breakthrough Infections in Metropolitan Detroit
por: sturla, Nicholas, et al.
Publicado: (2021)

357. Complications and Outcomes of Obese Patients Hospitalized with COVID-19
por: Shallal, Anita, et al.
Publicado: (2020)

753. Performance Characteristics of Diagnostic Assays in Blastomycosis
por: O’Dowd, Timothy, et al.
Publicado: (2020)

708. Three Stages of Laboratory Stewardship in Improving Appropriate Clostridiodes Difficile Testing
por: Beckman, Shannon, et al.
Publicado: (2023)

2424. Shedding of Viable Clostridiodes difficile in Patients Admitted to a Medical Intensive Care Unit
por: Young, Vincent B, et al.
Publicado: (2019)

209. Antibiotic Utilization During the COVID-19 Surge in Detroit
por: Shallal, Anita, et al.
Publicado: (2020)

Role of diagnostic stewardship in reducing healthcare-facility–onset Clostridioides difficile infections
por: Shallal, Anita B., et al.
Publicado: (2023)

Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections
por: Suleyman, Geehan, et al.
Publicado: (2022)

2346. Cost Savings Associated with Implementation of Clinical Decision Support for Clostridiodes difficile Testing
por: Hoegg, Cindy L, et al.
Publicado: (2019)

Role of diagnostic stewardship in reducing healthcare facility-onset Clostridioides difficile infections
por: Shallal, Anita, et al.
Publicado: (2022)

2379. It’s Getting Complicated: Outcomes of Clostridiodes difficile PCR Positive/Toxin-Negative Patients
por: Morillas, Jose A, et al.
Publicado: (2019)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

407. Utilization of Blood Cultures, Risk factors and Outcomes of Bloodstream Infections in Patients Hospitalized with COVID-19
por: Gudipati, Smitha, et al.
Publicado: (2020)

2359. Prospective Feasibility Study for Novel Ultrasensitive Multiplexed Immunoassay for Clostridiodes difficile Toxins A and B
por: Watson, Lauren, et al.
Publicado: (2019)

397. Oral Vancomycin Versus Fidaxomicin for Clostridiodes difficile: A Comparative Retrospective Evaluation across a Large, Multi-center Healthcare System
por: Roemer, Kaleb, et al.
Publicado: (2022)

Updates and Opinions in Diagnosis and Treatment of Clostridiodes difficile in Pediatrics
por: Malhotra, Sanchi, et al.
Publicado: (2021)

Evidence of within-facility patient–patient Clostridiodes difficile infection spread across diverse settings
por: Justice, Samuel, et al.
Publicado: (2022)

2661. Characterization of Mpox in Southeast Michigan
por: Alvi, Rija B R, et al.
Publicado: (2023)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

Risk for Clostridiodes difficile Infection among Older Adults with Cancer
por: Kamboj, Mini, et al.
Publicado: (2019)

A Predictive Model to Identify Complicated Clostridiodes difficile Infection
por: Berinstein, Jeffrey A, et al.
Publicado: (2023)

2384. The Relationship Between Rifaxamin Use and the Prevalence of Clostridiodes difficile and Vancomycin-Resistant Enterococcus in Patients with Advanced Liver Disease
por: Alberto. De Jesus, Francisco, et al.
Publicado: (2019)

1628 Accuracy of Healthcare Facility-Onset Clostridium difficile Classification
por: Trappler, Regan, et al.
Publicado: (2014)

505. Bezlotoxumab Reduces Recurrence of Clostridium difficile Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
por: Askar, Sally, et al.
Publicado: (2018)

Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by Clostridiodes difficile
por: Sánchez-Pellicer, Pedro, et al.
Publicado: (2021)

386. Long-term Complications Associated with COVID-19 Infection
por: Gudipati, Smitha, et al.
Publicado: (2020)

Management and characteristics of patients suffering from Clostridiodes difficile infection in primary care
por: Klezovich-Bénard, Maria, et al.
Publicado: (2021)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_52tgqgjae6ed9nbjpra5kc233i